[go: up one dir, main page]

NO20060027L - Antistoffer mot bindevevsvekstfaktor - Google Patents

Antistoffer mot bindevevsvekstfaktor

Info

Publication number
NO20060027L
NO20060027L NO20060027A NO20060027A NO20060027L NO 20060027 L NO20060027 L NO 20060027L NO 20060027 A NO20060027 A NO 20060027A NO 20060027 A NO20060027 A NO 20060027A NO 20060027 L NO20060027 L NO 20060027L
Authority
NO
Norway
Prior art keywords
antibodies
growth factor
connective tissue
tissue growth
ctgf
Prior art date
Application number
NO20060027A
Other languages
English (en)
Other versions
NO336451B1 (no
Inventor
Thomas B Neff
Al Y Lin
Noelynn A Oliver
William R Usinger
Qingjiah Wang
David A Yeowell
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of NO20060027L publication Critical patent/NO20060027L/no
Publication of NO336451B1 publication Critical patent/NO336451B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)

Abstract

SAMMENDRAG Den foreliggende oppfinnelsen gjelder antistoffer som bindes til CTGF. Antistoffene er spesielt rettet mot områder i CTGF som deltar i biologiske aktiviteter forbundet med fibrose. Oppfinnelsen gjelder også fremgangsmåter for anvendelse av antistoffene for behandling av lidelser forbundet med CTGF innbefattet lokaliserte og systemiske fibrotiske lidelser innbefattet lidelser i lunge, lever, hjerte, hud og nyre.
NO20060027A 2003-06-04 2006-01-03 Antistoffer mot bindevevsvekstfaktor, farmasøytisk sammensetning omfattende nevnte antistoff, og anvendelser derav, samt par av rekombinante polynukleotider og vertsceller transfektert med nevnte polynukleotider NO336451B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47559803P 2003-06-04 2003-06-04
US10/858,186 US7405274B2 (en) 2003-06-04 2004-06-01 Connective tissue growth factor antibodies
PCT/US2004/017080 WO2004108764A2 (en) 2003-06-04 2004-06-02 Connective tissue growth factor antibodies

Publications (2)

Publication Number Publication Date
NO20060027L true NO20060027L (no) 2006-01-03
NO336451B1 NO336451B1 (no) 2015-08-24

Family

ID=33493433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060027A NO336451B1 (no) 2003-06-04 2006-01-03 Antistoffer mot bindevevsvekstfaktor, farmasøytisk sammensetning omfattende nevnte antistoff, og anvendelser derav, samt par av rekombinante polynukleotider og vertsceller transfektert med nevnte polynukleotider

Country Status (16)

Country Link
US (9) US7405274B2 (no)
EP (3) EP1631591B1 (no)
JP (2) JP5624707B2 (no)
KR (1) KR101244113B1 (no)
CN (2) CN1829740B (no)
AT (1) ATE538136T1 (no)
AU (1) AU2004245514B2 (no)
BR (1) BRPI0410963B8 (no)
CA (1) CA2526509C (no)
DK (1) DK1631591T3 (no)
ES (1) ES2379662T3 (no)
IL (1) IL172328A (no)
NO (1) NO336451B1 (no)
NZ (1) NZ543522A (no)
RU (1) RU2330861C2 (no)
WO (1) WO2004108764A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100664625B1 (ko) * 1998-12-14 2007-01-04 유니버시티 오브 마이애미 결합 조직 성장인자 단편, 그의 제조 방법 및 그의 용도
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
CN101884789A (zh) 2004-02-11 2010-11-17 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
AU2005244154C1 (en) * 2004-04-28 2010-07-01 Fibrogen, Inc. Treatments for pancreatic cancer
JP2008540456A (ja) * 2005-05-05 2008-11-20 ファイブローゲン、インコーポレーテッド 血管疾患の治療
JP2009510056A (ja) * 2005-09-29 2009-03-12 ファイブローゲン、インコーポレーテッド 血圧を低下させる方法
JP2008295328A (ja) 2007-05-30 2008-12-11 Fujifilm Corp 卵巣癌の検出方法、及び抑制方法
US8796443B2 (en) * 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
RU2392960C1 (ru) * 2008-09-26 2010-06-27 Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) Способ коррекции плотности соединительной ткани
WO2010042202A1 (en) * 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
WO2010042201A1 (en) * 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of focal segmental glomerulosclerosis
EP2221387A1 (en) * 2009-02-19 2010-08-25 Université de la Méditerranée Fibrosis susceptibility gene and uses thereof
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
US8771692B2 (en) * 2009-07-02 2014-07-08 Fibrogen, Inc. Methods for treatment of muscular dystrophy
WO2011056234A1 (en) * 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
CA2794187C (en) 2010-03-24 2020-07-14 Rxi Pharmaceuticals Corporation Rna interference in ocular indications
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
WO2012100262A1 (en) 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
US20140065162A1 (en) * 2011-11-08 2014-03-06 Fibrogen, Inc. Compositions and Methods for Treating Brain Tumors
WO2013094723A1 (ja) 2011-12-22 2013-06-27 アステラス製薬株式会社 新規抗ヒトｃｔｇｆ抗体
WO2013108869A1 (ja) * 2012-01-20 2013-07-25 国立大学法人岡山大学 がんの治療又は予防剤
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
ES2718472T3 (es) 2012-05-03 2019-07-02 Fibrogen Inc Métodos para tratar fibrosis pulmonar idiopática
KR102221499B1 (ko) * 2013-09-26 2021-03-02 갈데르마 소시에떼아노님 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
CN104740628B (zh) * 2015-02-12 2017-09-26 西安交通大学医学院第一附属医院 用于治疗肝纤维化的结缔组织生长因子嵌合疫苗及其应用
WO2016205226A1 (en) 2015-06-15 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating affective disorders
ES2844899T3 (es) * 2015-12-10 2021-07-23 Fibrogen Inc Métodos para el tratamiento de enfermedades de las neuronas motoras
EP3469080A4 (en) 2016-06-13 2020-01-22 The University of North Carolina at Chapel Hill OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE
WO2019221576A1 (ko) * 2018-05-17 2019-11-21 광주과학기술원 Ccn5를 유효성분으로 포함하는 망막질환 예방 또는 치료용 약학 조성물
WO2020009248A1 (ja) * 2018-07-04 2020-01-09 京都府公立大学法人 眼組織の線維化抑制用組成物
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
BR112021023669A2 (pt) 2019-06-04 2022-03-29 Jiangsu Hengrui Medicine Co Anticorpo do fator de crescimento de tecido anti-conjuntivo e aplicação do mesmo
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
CN115286714B (zh) * 2020-10-27 2024-07-23 温州医科大学 一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用
KR20230117161A (ko) * 2020-12-03 2023-08-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-결합 조직 성장 인자 항체를 포함하는 약학 조성물
CN115645525B (zh) * 2022-12-14 2023-04-14 北京大学第三医院（北京大学第三临床医学院） Ctgf中和抗体在制备防治绝经后骨关节炎的药物中的应用
TW202502816A (zh) * 2023-03-10 2025-01-16 大陸商上海濟煜醫藥科技有限公司 一種靶向ｃｔｇｆ的抗體或其抗原結合片段及其應用
US12121561B1 (en) 2024-02-17 2024-10-22 King Faisal University Composition for treating or preventing insulin resistance

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587670A (en) 1897-08-03 Combined high-pressure throttle and reducing valve
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5837258A (en) * 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
AU3536495A (en) 1994-09-15 1996-03-29 Fred Nordberg Electric fence device
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
JPH11180895A (ja) * 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
JP4537507B2 (ja) * 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
EP1043335A4 (en) 1997-12-25 2005-08-31 Japan Tobacco Inc MONOCLONAL ANTIBODY AGAINST THE BIND WEIGHT GROWTH FACTOR AND ITS MEDICAL USES
EP1112088B1 (en) 1998-09-08 2010-10-27 Henry Ford Health System Method for detecting connective tissue growth factor for diagnosing a renal disorder
US6348329B1 (en) 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
KR100664625B1 (ko) 1998-12-14 2007-01-04 유니버시티 오브 마이애미 결합 조직 성장인자 단편, 그의 제조 방법 및 그의 용도
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2002326939A1 (en) * 2001-09-18 2003-04-01 Fibrogen, Inc. Methods of assaying connective tissue growth factor
JP2005519881A (ja) 2001-12-11 2005-07-07 ファイブローゲン、インコーポレーテッド 眼プロセスの抑制方法
US20190127456A1 (en) * 2017-10-31 2019-05-02 Fibrogen, Inc. Methods of treating idiopathic pulmonary fibrosis

Also Published As

Publication number Publication date
KR20060030032A (ko) 2006-04-07
AU2004245514A1 (en) 2004-12-16
HK1094336A1 (zh) 2007-05-04
CN103539858A (zh) 2014-01-29
IL172328A (en) 2012-01-31
NZ543522A (en) 2008-06-30
CA2526509A1 (en) 2004-12-16
NO336451B1 (no) 2015-08-24
JP2007525194A (ja) 2007-09-06
DK1631591T3 (da) 2012-04-10
US20140073047A1 (en) 2014-03-13
EP2338914A1 (en) 2011-06-29
CN1829740A (zh) 2006-09-06
CN1829740B (zh) 2013-05-29
ATE538136T1 (de) 2012-01-15
EP2322549A1 (en) 2011-05-18
US20040248206A1 (en) 2004-12-09
JP5624707B2 (ja) 2014-11-12
JP5753506B2 (ja) 2015-07-22
US20160024198A1 (en) 2016-01-28
BRPI0410963B8 (pt) 2021-05-25
US7405274B2 (en) 2008-07-29
RU2005141492A (ru) 2007-07-20
JP2012143239A (ja) 2012-08-02
US20160257740A1 (en) 2016-09-08
KR101244113B1 (ko) 2013-03-18
US20090017043A1 (en) 2009-01-15
US20210230259A1 (en) 2021-07-29
US20110091468A1 (en) 2011-04-21
ES2379662T3 (es) 2012-04-30
US20190023778A1 (en) 2019-01-24
BRPI0410963B1 (pt) 2019-10-08
EP1631591A2 (en) 2006-03-08
US9034643B2 (en) 2015-05-19
US7871617B2 (en) 2011-01-18
WO2004108764A2 (en) 2004-12-16
RU2330861C2 (ru) 2008-08-10
WO2004108764A3 (en) 2005-03-03
AU2004245514B2 (en) 2009-10-01
CA2526509C (en) 2013-08-06
US20240076364A1 (en) 2024-03-07
EP1631591B1 (en) 2011-12-21
BRPI0410963A (pt) 2006-07-04

Similar Documents

Publication Publication Date Title
NO20060027L (no) Antistoffer mot bindevevsvekstfaktor
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
TNSN05300A1 (en) Treatment with anti-vegf antibodies
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
EA200600254A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
WO2006020773A3 (en) Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
WO2006014729A3 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2003083041A3 (en) Cripto-specific antibodies
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
NO20076241L (no) Terapier for vaskulaere sykdommer
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
WO2006047032A3 (en) Indole compounds useful as serotonin selective agents
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
WO2006109044A3 (en) Selective modulation of tumour necrosis factor receptors in therapy
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole